Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Apellis Pharmaceuticals Inc fell by 200.78m. Cash Flow from Financing totalled 394.50m or 99.47% of revenues. In addition the company used 594.74m for operations while cash used for investing totalled 674.00k.
Cash flow per share | -2.02 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.94 |
---|---|
Tangible book value per share | 1.94 |
More ▼
Balance sheet in USDView more
Current ratio | 4.36 |
---|---|
Quick ratio | 3.73 |
Total debt/total equity | 1.91 |
---|---|
Total debt/total capital | 0.656 |
More ▼